Jelle Demeestere

Jelle Demeestere

Auto-generated profile, based on publicly available information

Jelle Demeestere

KU Leuven, Leuven Brain Institute, Department of Neurosciences, Experimental Neurology, Belgium (J.D., L.M., A.W.).

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NLNatalie E. LeCouffe
Natalie E. LeCouffe
MKManon Kappelhof
Manon Kappelhof
KTKilian M. Treurniet
Kilian M. Treurniet
LRLeon A. Rinkel
Leon A. Rinkel
ABAgnetha E. Bruggeman
Agnetha E. Bruggeman
YRYvo B.W.E.M. Roos
Yvo B.W.E.M. Roos
The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations. We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause and symptomatic intracerebral hemorrhage were the main safety end points. The analysis included 539 patients. The median score on the modified Rankin scale at 90 days was 3 (interquartile range, 2 to 5) with EVT alone and 2 (interquartile range, 2 to 5) with alteplase plus EVT. The adjusted common odds ratio was 0.84 (95% confidence interval [CI], 0.62 to 1.15; P=0.28), which showed neither superiority nor noninferiority of EVT alone. Mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT (adjusted odds ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic intracerebral hemorrhage occurred in 5.9% and 5.3% of the patients in the respective groups (adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81). In a randomized trial involving European patients, EVT alone was neither superior nor noninferior to intravenous alteplase followed by EVT with regard to disability outcome at 90 days after stroke. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by the Collaboration for New Treatments of Acute Stroke consortium and others; MR CLEAN–NO IV ISRCTN number, ISRCTN80619088.)

1 March 2020 in Stroke
Verified
Journal Article
Closed access
PDF file
JDJelle Demeestere
Jelle Demeestere
AWAnke Wouters
Anke Wouters
SCSoren Christensen
Soren Christensen
RLRobin Lemmens
Robin Lemmens
MLMaarten G. Lansberg
Maarten G. Lansberg

29 June 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
Urs FisherUrs Fisher
Urs Fisher
MKMasatoshi Koga
Masatoshi Koga
DSDaniel Strbian
Daniel Strbian
MBMattia Branca
Mattia Branca
SAStefanie Abend
Stefanie Abend
JDJesse Dawson
Jesse Dawson
The effect of early as compared with later initiation of direct oral anticoagulants (DOACs) in persons with atrial fibrillation who have had an acute ischemic stroke is unclear. We performed an investigator-initiated, open-label trial at 103 sites in 15 countries. Participants were randomly assigned in a 1:1 ratio to early anticoagulation (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke) or later anticoagulation (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke). Assessors were unaware of the trial-group assignments. The primary outcome was a composite of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death within 30 days after randomization. Secondary outcomes included the components of the composite primary outcome at 30 and 90 days. Of 2013 participants (37% with minor stroke, 40% with moderate stroke, and 23% with major stroke), 1006 were assigned to early anticoagulation and 1007 to later anticoagulation. A primary-outcome event occurred in 29 participants (2.9%) in the early-treatment group and 41 participants (4.1%) in the later-treatment group (risk difference, -1.18 percentage points; 95% confidence interval [CI], -2.84 to 0.47) by 30 days. Recurrent ischemic stroke occurred in 14 participants (1.4%) in the early-treatment group and 25 participants (2.5%) in the later-treatment group (odds ratio, 0.57; 95% CI, 0.29 to 1.07) by 30 days and in 18 participants (1.9%) and 30 participants (3.1%), respectively, by 90 days (odds ratio, 0.60; 95% CI, 0.33 to 1.06). Symptomatic intracranial hemorrhage occurred in 2 participants (0.2%) in both groups by 30 days. In this trial, the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death at 30 days was estimated to range from 2.8 percentage points lower to 0.5 percentage points higher (based on the 95% confidence interval) with early than with later use of DOACs. (Funded by the Swiss National Science Foundation and others; ELAN ClinicalTrials.gov number, NCT03148457.).

8 June 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
RNRaul G. Nogueira
Raul G. Nogueira
MQMuhammad M. Qureshi
Muhammad M. Qureshi
MAMohamad Abdalkader
Mohamad Abdalkader
SMSheila Ouriques Martins
Sheila Ouriques Martins
HYHiroshi Yamagami
Hiroshi Yamagami
ORon behalf of the SVIN COVID-19 Global Stroke Registry
on behalf of the SVIN COVID-19 Global Stroke Registry
Objective To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95% confidence interval [CI] −11.7 to −11.3, p < 0.0001) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95% CI −13.8 to −12.7, p < 0.0001) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95% CI −13.7 to −10.3, p = 0.001). Recovery of stroke hospitalization volume (9.5%, 95% CI 9.2–9.8, p < 0.0001) was noted over the 2 later (May, June) vs the 2 earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was noted in 3.3% (1,722/52,026) of all stroke admissions. Conclusions The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID-19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.

1 October 2018 in Stroke
Verified
Journal Article
Closed access
JDJelle Demeestere
Jelle Demeestere
LSLauranne Scheldeman
Lauranne Scheldeman
SCSandra A. Cornelissen
Sandra A. Cornelissen
SHSam Heye
Sam Heye
AWAnke Wouters
Anke Wouters
RLRobin Lemmens
Robin Lemmens
Background and Purpose—: We aimed to compare the ability of conventional Alberta Stroke Program Early CT Score (ASPECTS), automated ASPECTS, and ischemic core volume on computed tomographic perfusion to predict clinical outcome in ischemic stroke because of large vessel occlusion ≤18 hours after symptom onset. Methods—: We selected patients with acute ischemic stroke from the CRISP study (Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke Project) with successful reperfusion (modified treatment in cerebral ischemia score 2b or 3). We used e-ASPECTS software to calculate automated ASPECTS and RAPID software to estimate ischemic core volumes. We studied associations between these imaging characteristics and good outcome (modified Rankin Scale score, 0–2) or poor outcome (modified Rankin Scale score, 4–6) in univariable and multivariable analysis, after adjustment for relevant clinical confounders. Results—: We included 156 patients. Conventional and automated ASPECTS was not associated with good or poor outcome in univariable analysis ( P =nonsignificant for all). Automated ASPECTS was associated with good outcome in multivariable analysis ( P =0.02) but not with poor outcome. Ischemic core volume was associated with good ( P <0.01) and poor outcome ( P =0.04) in univariable and multivariable analysis ( P =0.03 and P =0.02, respectively). Computed tomographic perfusion predicted good outcome with an area under the curve of 0.62 (95% CI, 0.53–0.71) and optimal cutoff core volume of 15 mL. Conclusions—: Ischemic core volume assessed on computed tomographic perfusion is a predictor of clinical outcome among patients in whom endovascular reperfusion is achieved ≤18 hours after symptom onset. In this population, conventional or automated ASPECTS did not predict outcome.

1 July 2017 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
JDJelle Demeestere
Jelle Demeestere
CGCarlos Garcia-Esperon
Carlos Garcia-Esperon
LLLongting Lin
Longting Lin
ABAndrew Bivard
Andrew Bivard
TATimothy Ang
Timothy Ang
CLChristopher Levi
Christopher Levi